NCT04155749View on ClinicalTrials.gov

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 23, 2019

Primary Completion Date

October 3, 2024

Study Completion Date

June 30, 2026

Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
DRUG

anitocabtagene-autoleucel

Chimeric Antigen Receptor T cells

Trial Locations (4)

53226

Froedtert Hospital/Medical College of Wisconsin, Milwaukee

60637

Advanced Cellular Therapeutics Facility, DCAM 0800A, Chicago

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Arcellx, Inc.
All Listed Sponsors
collaborator

Arcellx, Inc.

INDUSTRY

lead

Kite, A Gilead Company

INDUSTRY

NCT04155749 - Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter